Singapore, June 9 -- Japan-based GNI Group Co. has entered into an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co. from shareholders led by Blackstone. The transaction values Ayumi Pharmaceutical Holdings at approximately Euro44.8 billion and will make the company a wholly owned subsidiary of GNI Group.

The acquisition significantly expands GNI Group's commercial presence in Japan and establishes a large-scale pharmaceutical platform that is expected to accelerate the introduction of innovative therapies, biosimilars, and internally developed products into the Japanese market. Following the transaction, GNI Group expects combined fiscal 2026 revenue to reach approximately Euro65.2 billion.

Ayumi Pharmaceutic...